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Abstract
Background: Anastomotic or marginal ulcers occur in 0.6 to 16% of patients after laparoscopic Roux-en-Y-Gastric
Bypass. Initial therapy aims at eliminating known risk factors including smoking, Helicobacter pylori infection, use of
non-steroidal anti-inflammatory drugs and inhibition of gastric acid secretion. While this approach is successful in
68 to 88% of the cases, up to one third of patients need a subsequent surgical revision. However, marginal ulcers
still recur in up to 10% of cases after revisional surgery, thus constituting a serious challenge for bariatric surgeons.
Case presentation: We herein report a case of an insidious marginal ulcer refractory to both medical therapy with
high-dosed proton pump inhibitors and sucralfate as well as surgical therapy consisting of the lengthening of a
short alimentary limb and later resection of the gastroenterostomy and construction of a new tension-free
anastomosis. Only after gastrectomy by laparoscopic en-bloc resection of the gastrojejunostomy, the gastric pouch
and resection of the gastric remnant with reconstruction by esophagojejunostomy the patient remained free of
symptoms.
Conclusion: By laparoscopic resection of the entire gastric pouch and the gastric remnant the risk to leave a
suboptimally vascularised or even ischemic pouch in situ was avoided. The esophagojejunostomy was then created
in healthy, good vascularised tissue. In our case this novel approach was effective in the management of a
refractory anastomotic ulcer and might represent a rescue option when simple revision of the gastrojejunostomy
fails.
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Background
A specific complication after laparoscopic Roux-en-Y-
Gastric-Bypass (LRYGB) is a marginal or anastomotic
ulcer (AU) occurring at the gastrojejunal anastomosis.
While AU can remain asymptomatic in 62-92% of the
cases [1-4], they can frequently cause disabling pain or
complications such as perforation and bleeding [5,6].
The incidence of AU varies from 0.6% to 16% in endo-
scopic studies [1-4].
The etiology of AU is unclear. Two classes of risk fac-
tors have been suggested: operative and patient related
factors. Although large gastric pouch, vertically oriented
pouch [7], gastro-gastric fistula [8], local tissue ischemia
due to anastomotic tension [9] or presence of foreign
bodies in the ulcer ground (e.g. nonabsorbable sutures)
[10] have been previously discussed, there is still a lack
of high level of evidence demonstrating these factors to
be significant. In contrast, better data exist for patient
related factors, showing that smoking (odds ratio (OR)
30.6), use of nonsteroidal anti-inflammatory drugs (OR
11.5) and lack of proton pump inhibitor (PPI) prophy-
laxis (OR 3) represent significant risk factors [11].* Correspondence: antonio.nocito@usz.ch1Department of Visceral and Transplantation Surgery, University Hospital
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Therefore, ulcer therapy starts with elimination of
patient related risk factors and inhibition of gastric acid
secretion. While this approach is successful in 68 to
88%, up to one third of the patients need a subsequent
surgical revision [8,12]. Although revision surgery is suc-
cessful in most cases, AU recur in up to 8% [8], thus
leading to a distressing situation for both patients and
bariatric surgeons.
We herein report a case of an insidious AU refractory
medical and surgical therapy, which finally required an
aggressive approach consisting of laparoscopic gastric
pouch and gastric remnant resection.
Case presentation
In a 50 year male patient with a BMI of 45 kg/m2 an
antecolic, antegastric LRYGB with a 100 cm alimentary
and a 60 cm biliary limb was performed. The gastrojeju-
nostomy was constructed using a 25 mm circular stapler
(EEA 2535, 3.5 mm Staples, Covidien®). Simultaneously,
a 6 cm silastic (Fobi) ring was placed around the gastro-
jejunostomy. A few weeks after discharge, the patient,
who continued smoking after surgery, presented with
strong epigastric pain, postprandial regurgitation and
vomiting. He was unable to eat solid food and to attend
work. Endoscopy revealed two AU at the gastrojejunost-
omy. Oral PPI therapy (esomeprazole, 80 mg/die) was
initiated and, since it was thought to be partly responsi-
ble for the symptoms, the silastic ring was removed.
Intravenous high-dose PPI (esomeprazole, 240 mg/die)
led to healing of the AU. However, epigastric pain and
regurgitation did not ameliorate. A 99 m Tc-mebrofenin
scintigraphy revealed severe biliary reflux. Seven months
after LRYGB the patient was referred to our department.
At the initial consultation the patient was taking up to
600 mg/day esomeprazole and 200 mg/day tilidin orally.
As an AU could not be detected further diagnostic
investigations were performed:
• Upper gastrointestinal (GI) contrast series revealing
a small gastric pouch without signs of a gastric fistula
and normal passage.
• Double balloon push enteroscopy demonstrating a
short (40 cm) alimentary limb.
• High-resolution esophageal manometry revealing a
normotensive propulsive peristalsis and a normotense
lower esophageal sphincter.
• 24 h-impedance pH-metry - performed under anta-
cid medication - showing no pathological acid or non-
acid reflux.
• MRI in Sellink technique showing no obstruction of
the small bowel.
Apart from the biliary reflux diagnosed by scintigraphy
consistent with a very short Roux-limb by push-entero-
scopy, no other reason for the epigastric pain was
detected. We performed a laparoscopic lengthening of
the Roux limb by additional 120 cm resulting in a new
alimentary limb of 160 cm. Oral PPI therapy (80 mg/
day) was continued and sucralfate (4 g/d) was added.
After a short period without pain and regurgitation,
symptoms recurred two weeks after Roux limb length-
ening. Despite PPI therapy endoscopy revealed a recur-
rent AU at the gastrojejunostomy (Figure 1). Therefore
a laparoscopic resection of the gastrojejunostomy was
performed followed by a construction of a new, tension-
free anastomosis using a 25 mm circular stapler (EEA
2535, 3.5 mm Staples, Covidien®). PPI therapy and
sucralfate were continued. Again the patient was dis-
charged free of symptoms on postoperative day five.
One month later and one year after initial LRYGB sur-
gery, the patient was again not free of epigastric pain.
Gastroscopy showed again a large AU at the gastroen-
terostomy. Meanwhile, the patient was finally motivated
enough to quit smoking and was enrolled in a stop-
smoking program. Since gastrin level was not elevated
(111 ng/l) an underlying gastrinoma could be excluded.
Furthermore, Helicobacter pylori and hyperparathyroid-
ism as additional potential causes for anastomotic ulcers
were also ruled out. Nevertheless, epigastric pain and
the AU persisted.
At this point an aggressive approach was decided con-
sisting of a gastrectomy by laparoscopic en-bloc resec-
tion of the gastrojejunostomy and the gastric pouch
with transsection 2 cm proximal to the angle of His and
resection of the gastric remnant (Figure 2). The gastro-
intestinal continuity was re-established by the construc-
tion of an esophagojejunostomy using a 25 mm circular
stapler (Figure 3). Two days after surgery an upper GI
contrast series showed no leakage or stenosis at the
level of the esophagojejunostomy. The patient was
Figure 1 Recurrent anastomotic ulcer in the intestinal part of
the gastrojejunostomy.
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discharged on postoperative day 10. Six months later the
patient was free of symptoms, he was able to start
opioid weaning and had regained 6 kg of weight. Finally,
endoscopy showed a regular esophagojejunostomy.
Discussion and conclusion
Our case of a persistently recurring AU is representative
for the current shortcomings in understanding the
pathogenesis and thus optimal treatment of AU. We
describe a successful approach for the management of
intractable AU.
After LRYGB up to 7% of patients develop upper GI
symptoms. Analysis and management of this condition is
often challenging as 32% of symptomatic patients show a
normal anatomy at endoscopy [13]. Conservative therapy
has been reported to be successful in 68%-88% of the
cases [8,12]. In our case, endoscopy showed no abnormal-
ities apart from a short Roux limb at the time of referral.
As a short Roux limb may facilitate biliary reflux causing
postoperative pain and AU [14], we decided to lengthen
the alimentary limb. Despite improvement of regurgitation
symptoms, epigastric pain and AU recurred.
Approximately one third of AU recur after medical
therapy. For these cases a redo of the gastrojejunostomy
with a success rate of 87% has been advised [8]. Before
we embarked on this strategy, we reevaluated whether
putative factors leading to a recurrence were present.
Endoscopy and GI contrast series excluded potential
operative risk factors. Therefore a resection of the gas-
trojejunostomy with subsequent PPI therapy was per-
formed. However, the ulcer recurred potentially due to
the inability of the patient to quit smoking.
After revision surgery for AU, a recurrence rate of 8%
has been described. In these cases, revision of the gas-
trojejunostomy combined with gastric remnant resection
has been advocated reducing gastrin-producing- and
parietal cells [8].
In contrast to the proposed simple revision of the ana-
stomosis, we opted for a laparoscopic resection of the
entire gastric pouch and the gastric remnant. By this
means, the risk to leave a suboptimally vascularised or
even ischemic pouch in situ was avoided since the resec-
tion was taken back to esophageal tissue. The circular
esophagojejunostomy was then created in healthy, good
vascularised tissue. Subsequently, the patient was free of
symptoms and no recurrence was observed after a fol-
low-up of 6 months. Hence, in our case this novel
approach was effective in the management of a refrac-
tory AU and might represent a rescue option when sim-
ple revision of the gastrojejunostomy fails.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any
Figure 2 Situs after en-bloc resection of the gastric pouch and
the gastrojejunostomy. (1 = esophagus, 2 = hepatoduodenal
ligament, 3 = caudate lobe).
Figure 3 Roux-Y reconstruction with esophagojejunostomy.
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accompanying images. A copy of the written consent is
available for review by the Editor-in-Chief of this
journal.
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